Name: Skin Works Medical Spa
Price range: $$

The most important difference is not that one drug is an injection and the other is a tablet. It is that they belong to different medication classes, are approved for different treatment durations, have different safety restrictions, and are supported by very different bodies of evidence.

SemaglutideGLP-1 receptor agonist. Wegovy is FDA-approved for chronic weight management in eligible patients.

PhentermineSympathomimetic appetite suppressant. FDA-approved only as a short-term adjunct for weight reduction.

No direct winner for everyoneMedical history, cardiovascular risk, tolerance, cost and treatment horizon all change the decision.

Semaglutide vs. Phentermine at a Glance

Feature	Semaglutide	Phentermine
Drug class	GLP-1 receptor agonist	Sympathomimetic amine anorectic
Typical route	Weekly injection in the Skin Works program	Oral tablet or capsule
FDA weight-management status	Wegovy is approved for chronic weight management in eligible patients	Approved only for short-term use, described in labeling as “a few weeks”
Evidence horizon	Large randomized trials extending beyond one year	Older and generally shorter randomized trials; longer-term monotherapy data are largely observational
Controlled substance	No	Yes, Schedule IV
Major practical issue	GI tolerability, titration, long-term access and cost	Stimulant effects, cardiovascular restrictions, tolerance and short-term labeling
Stopping treatment	Weight regain is common after discontinuation	Appetite and weight may also return after treatment; long-term maintenance evidence is more limited

How Do They Work?

Semaglutide

Semaglutide is a GLP-1 receptor agonist. It acts on pathways involved in appetite and food intake, slows gastric emptying, and affects glucose regulation. For weight management, the FDA-approved semaglutide product is Wegovy.

Semaglutide is deliberately titrated upward rather than started at a full maintenance dose. That slower escalation is designed to improve tolerability, especially for gastrointestinal side effects.

Phentermine

Phentermine is a sympathomimetic amine that suppresses appetite through central nervous system stimulation. The current prescribing information describes it as chemically and pharmacologically related to amphetamines, but it is not accurate to simply call it “an amphetamine.”

Phentermine is a Schedule IV controlled substance. Its FDA indication is short-term monotherapy as part of a broader weight-reduction plan that includes diet, exercise and behavioral modification.

Which Produces More Weight Loss?

The strongest semaglutide obesity evidence comes from the STEP program. In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to semaglutide 2.4 mg or placebo, both with lifestyle intervention. At 68 weeks, mean weight change was -14.9% with semaglutide versus -2.4% with placebo.

Phentermine can also produce clinically meaningful weight loss. In one 12-week randomized placebo-controlled study of 74 adults, phentermine 30 mg produced an average loss of 8.1 kg versus 1.7 kg with placebo. Other trials have used different doses and durations.

These numbers are not a head-to-head comparison. The semaglutide and phentermine studies enrolled different populations, lasted for different lengths of time and used different designs. The evidence supports saying semaglutide has a stronger long-term trial base, not that a 14.9% STEP result can simply be placed beside a short phentermine trial and treated as a direct contest.

Longer-term phentermine use has also been studied in real-world cohorts. A 2019 observational study of nearly 14,000 adults found greater weight loss among longer-term users without a detected increase in cardiovascular disease or death among lower-risk individuals. That is useful evidence, but it does not change the FDA-approved monotherapy indication, which remains short-term.

Short-Term Drug vs. Chronic-Treatment Drug

This is one of the clearest differences between the two medications.

Wegovy is approved for chronic weight management. That means it is intended for ongoing treatment when clinically appropriate, rather than a brief appetite-suppression course.

Phentermine is approved only for short-term use. Its current label says “a few weeks.” Longer-term prescribing occurs in clinical practice, but that use is outside the traditional FDA-labeled duration for phentermine monotherapy.

Obesity itself is a chronic disease, so patients should discuss the maintenance plan before starting either medication. A short period of appetite suppression without a post-treatment strategy is not the same as long-term weight management.

What Happens After Semaglutide Is Stopped?

Semaglutide should not be described as automatically producing “sustainable” weight loss after the medication is discontinued.

In the STEP 1 extension, participants who had completed 68 weeks of semaglutide treatment were followed after treatment stopped. During the following year, participants regained about two-thirds of the weight they had previously lost, and many cardiometabolic improvements moved back toward baseline.

That finding does not mean semaglutide failed. It reinforces that obesity biology persists after medication withdrawal and that long-term maintenance needs to be planned rather than assumed.

What About Heart and Cardiovascular Risk?

This is another major difference.

In 2024, the FDA approved an additional Wegovy indication to reduce the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight. In the cardiovascular outcomes trial, major cardiovascular events occurred in 6.5% of Wegovy-treated participants versus 8.0% of placebo-treated participants.

Phentermine does not carry an equivalent cardiovascular-risk-reduction indication. Its label instead lists a history of cardiovascular disease, including coronary artery disease, stroke, arrhythmias, congestive heart failure and uncontrolled hypertension, among its contraindications.

Side Effects and Important Safety Differences

Semaglutide	Phentermine
Nausea, diarrhea, vomiting, constipation and abdominal symptoms are common, particularly during dose escalation.	Dry mouth, insomnia, restlessness, increased heart rate and blood-pressure effects can occur.
Important warnings include pancreatitis, gallbladder disease, dehydration-related kidney injury, hypersensitivity and diabetic-retinopathy complications in some patients with diabetes.	Contraindicated in people with a history of cardiovascular disease or uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, pregnancy, nursing, and recent MAO-inhibitor use.
Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.	Phentermine is Schedule IV and its labeling specifically addresses abuse, dependence and tolerance.

Pregnancy is an important consideration for both medications. Weight-loss drugs are not used during pregnancy. Wegovy labeling instructs patients to discontinue semaglutide at least two months before a planned pregnancy because of its long half-life.

A 2026 FDA review also found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of that warning from affected GLP-1 weight-management labels. That is a useful update because older semaglutide articles and labels may still display the previous warning.

Which Works Faster?

Phentermine can produce appetite suppression quickly because it is a stimulant medication taken daily. Semaglutide is intentionally started at a low dose and titrated upward over time.

But “which works faster?” is not the same question as “which produces more weight loss?” There is no strong direct trial establishing that one medication produces faster clinically meaningful weight loss than the other under otherwise identical conditions.

Patients should be cautious with claims such as “phentermine works immediately while semaglutide is slow.” Appetite sensation can change quickly, but meaningful weight loss is measured over weeks and months.

Can Semaglutide and Phentermine Be Taken Together?

This should not be presented as a routine combination.

The current phentermine prescribing information states that phentermine is indicated only as short-term monotherapy and that the safety and effectiveness of combining it with other weight-loss drugs have not been established. The label therefore says coadministration with other weight-loss drugs is not recommended.

Some clinicians may make individualized off-label prescribing decisions, but patients should understand that this is different from an FDA-approved combination strategy with established safety and efficacy.

A 2026 Note About Compounded Semaglutide

“Semaglutide” describes the active ingredient, but not every semaglutide product is FDA-approved.

FDA-approved products undergo review for safety, effectiveness, quality, manufacturing and labeling. Compounded semaglutide products are not FDA-approved and do not undergo that same premarket review.

The FDA declared the semaglutide injection shortage resolved in February 2025. It has since tightened enforcement around compounded products that are essentially copies of commercially available approved drugs. The FDA has also warned about dosing errors with compounded injectable semaglutide and has cautioned against salt forms such as semaglutide sodium or semaglutide acetate.

If compounded medication is being considered, patients should ask which licensed pharmacy supplies it, the exact active ingredient and concentration, how dosing is measured, and why a compounded preparation is medically appropriate for that individual patient.

Which Medication May Fit Which Type of Patient?

Clinical consideration	What it means for the discussion
Long-term obesity treatment	Semaglutide has an FDA-approved chronic weight-management indication and substantially stronger long-duration randomized evidence.
Preference for an oral medication	Phentermine may be easier from an administration standpoint, but stimulant risks and short-term labeling still apply.
Established cardiovascular disease	Wegovy has an FDA-approved cardiovascular-risk-reduction indication in eligible adults. Phentermine has important cardiovascular contraindications.
History of MTC or MEN2	Wegovy is contraindicated.
Uncontrolled hypertension or cardiovascular disease	Phentermine is contraindicated.
Concern about cost	Phentermine is generally less expensive as a medication, but total program cost and medical eligibility should be compared, not medication sticker price alone.
Need for substantial average weight reduction	Semaglutide has much stronger evidence for double-digit average percentage weight loss over long-term treatment.

Current Skin Works Pricing

Skin Works currently lists semaglutide treatment in Torrance starting with a $370 starter package that includes the lower-dose initiation phase. Current listed semaglutide package prices rise with dose, up to $665 for the highest listed package.

The current price file separately lists phentermine at $35. That line item should not be treated as an apples-to-apples comparison with the semaglutide program price because medical evaluation, prescription-related charges, monitoring and follow-up may differ. Patients should request the complete written price for the treatment plan they are actually being prescribed.

For current semaglutide program details, see Semaglutide Weight Loss in Torrance. Patients comparing incretin medications can also review Tirzepatide vs. Semaglutide.

So, Which One Works Better?

If “works better” means greater average weight loss supported by long-term randomized evidence, semaglutide has the stronger evidence base.

If the question is whether phentermine can be useful, the answer is also yes for appropriately selected patients. It is inexpensive, oral, and has evidence of short-term efficacy. But it has stimulant-related contraindications, is a Schedule IV controlled substance and is not FDA-approved as chronic monotherapy.

The decision should therefore be based on medical eligibility, treatment horizon, expected benefit, side-effect tolerance, cardiovascular history, pregnancy plans, cost and the maintenance strategy after weight loss begins.

The medication is only one part of the plan.

Before starting either drug, patients should know why it was selected, what result is realistic, what monitoring is required, how side effects will be handled, what the total cost is, and what the maintenance plan will be if treatment is stopped.

Frequently Asked Questions

Is semaglutide stronger than phentermine?

Semaglutide has stronger evidence for larger average long-term weight reduction, but there is no definitive head-to-head trial showing that every patient will lose more weight on semaglutide than on phentermine.

Is phentermine approved for long-term use?

No. Current U.S. labeling describes phentermine as a short-term treatment for a few weeks. Longer prescribing occurs in practice and has observational evidence, but it is not the same as an FDA-approved chronic-weight-management indication.

Is phentermine addictive?

Phentermine is a Schedule IV controlled substance. Its prescribing information warns about abuse, dependence and tolerance. “Low to moderate addiction risk” is too imprecise to use as a universal patient description.

Can semaglutide and phentermine be combined?

The phentermine label states that safety and efficacy of combining phentermine with other weight-loss drugs have not been established and that coadministration is not recommended. Any off-label combination decision requires individualized medical judgment.

Will weight come back after stopping semaglutide?

Weight regain is common. In the STEP 1 extension, participants regained about two-thirds of their prior semaglutide-associated weight loss during the year after treatment was withdrawn.

Which is cheaper?

Phentermine is generally much less expensive as a medication. However, patients should compare total treatment cost, including evaluation, monitoring, follow-up and the duration of therapy, rather than comparing one medication line item with a monthly semaglutide program.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved semaglutide product. Compounded semaglutide is not FDA-approved and does not undergo FDA premarket review for safety, effectiveness or quality. Patients should know exactly which product and pharmacy are being used.

Sources & Medical References

This article is educational and does not replace individualized medical care. Semaglutide and phentermine are prescription medications with different indications, contraindications and monitoring requirements. Eligibility should be determined after medical evaluation.

Semaglutide vs. Phentermine: Which Is Better for Weight Loss?